Compare Mesoblast Limited (MESO) vs NetEase Inc (NTES) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs NetEase Inc — how do they compare? Mesoblast Limited trades at $13.8 (market cap $1.81B), while NetEase Inc trades at $122.5 (market cap $76.90B). The key difference: NetEase Inc is far larger — about 42.5× Mesoblast Limited's market cap, and NetEase Inc pays a 2.43% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 14 Days and NetEase Inc for 74 Days on average.
| MESO | NTES | |
|---|---|---|
Market Cap | $1.81B | $76.90B |
Volume | 240,620 | 494,839 |
Sector | Health | Technology |
52-Week High | $20.96 | $152.85 |
52-Week Low | $13.19 | $109.26 |
Typical Hold Time | 14 Days | 74 Days |
Enterprise Value | $1.89B | $52.62B |
Dividend Yield | — | 2.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.94, up 2.42% on the day, amid a bearish technical signal from moving averages. The company reported a significant revenue increase to $120 million in 2026, up from $17 million in 2025, but remains unprofitable with a net loss of $58 million. Recent milestones include FDA approval for a new potency assay for Ryoncil and completion of a Phase 3 trial for chronic back pain treatment, positioning it for potential future growth.
The outlook is cautiously optimistic due to strong revenue growth and key regulatory progress, yet high cash burn and persistent losses present substantial risks. Analyst sentiment is mixed, with a 45% buy rating, but the stock faces headwinds from its negative profit margins and competitive pressures in the biotech sector.
NTES trades at $119.60, up 0.45% today, with a neutral technical signal. The company reported Q2 2026 revenue of $4.4 billion, up 8% year-over-year, though EPS missed estimates due to investment losses. Gross margins improved significantly, and the balance sheet remains strong with $137.58 billion in cash. Revenue growth has been steady, with 2025 revenue reaching $112.63 billion and net income at $33.76 billion.
The outlook is positive given strong profitability, a robust balance sheet, and analyst consensus favoring a buy rating with a $168 price target. Risks include earnings volatility, competitive pressures in gaming, and macroeconomic headwinds affecting Chinese tech stocks. The stock presents a value opportunity with a P/E of 16.06, below industry averages.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About NetEase Inc
NetEase, which started on an internet portal service in 1997, is a leading online services provider in China. Its key services include online/mobile games, cloud music, media, advertising, email, live streaming, online education, and e-commerce. The company develops and operates some of the China's most popular PC client and mobile games, and it partners with global leading game developers, such as Blizzard Entertainment and Mojang (a Microsoft subsidiary).
Read more on NTES →
